Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
To make clinical trials more affordable and lead to the results needed for approval, MarkLogic has set up a new hub designed to do just that.
Janssen has become the latest Big Pharma to delve deeper into AI's potential to boost the number of successful drugs coming through the pipeline.
Adimab is continuing a dealmaking streak with three more deal expansions, with Novartis, Regeneron and Takeda.
WuXi AppTec’s CRO arm WuXi Clinical will subsume Pharmapace into its business as the China giant looks to up its trial services in biometrics.
AI in drug development is among the hottest buzzwords in biopharma right now, but real progress is hampered by lack of expertise and access.
Charles River Labs has been hit by “a highly sophisticated, well-resourced intruder” who hacked into 1% of its clients' data.
The Michael J. Fox Foundation and 23andMe are launching a network aimed at combining the patient voice and genetic data from Parkinson’s patients.
AstraZeneca tapped BenevolentAI to help bring artificial intelligence and machine learning to its drug discovery projects aimed at CKD and IPF.
The vast majority of universities are failing to comply with EU rules on the reporting of clinical trial results.
LabCorp’s CRO business Covance will boost its nonclinical services business as its parent company buys out the segment from Envigo.
